

MLN Matters Number: MM3191

Related Change Request (CR) #: 3191

Related CR Release Date: April 1, 2004

Effective Date: April 1, 2004

Related CR Transmittal #: 9

Implementation Date: April 3, 2004

## Ocular Photodynamic Therapy (OPT) with Verteporfin for Age-Related Macular Degeneration (AMD)

Note: This article was updated on May 7, 2013, to reflect current Web addresses. All other information remains unchanged.

### Provider Types Affected

All Medicare providers

### Provider Action Needed



#### STOP – Impact to You

This National Coverage Determination (NCD) provides for a change in the Medicare coverage policy for the use of Ocular Photodynamic Therapy (OPT) with verteporfin for age-related macular degeneration (AMD). Under certain conditions (described below), OPT with verteporfin for AMD will now be covered for additional clinical indications.



#### CAUTION – What You Need to Know


CMS has determined that, provided certain criteria are met, OPT with verteporfin (CPT codes 67221 and 67225, as well as HCPCS code J3395) will now be covered for AMD in two additional clinical instances:

- 1) subfoveal occult lesions with no classic choroidal neovascularization (CNV); and
- 2) subfoveal minimally classic CNV associated with AMD.

Note: HCPCS code J3396 should be used instead of J3395 for services on or after January 1, 2005.

#### Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents.

**GO – What You Need to Do**

Make sure that your billing staffs are aware of these coverage changes.

## Background

---

This NCD is documented in revisions to Chapters 80.2 and 80.3 of Pub. 100-03. Remember that NCDs are binding on all Medicare carriers, fiscal intermediaries, quality improvement organizations, health maintenance organizations, competitive medical plans, and health care prepayment plans. An NCD is also binding on Medicare + Choice Organizations. Administrative Law Judges may not review NCDs.

This NCD addresses coverage for the use of OPT with verteporfin in additional clinical instances. OPT with verteporfin continues to be approved for patients with a diagnosis of neovascular AMD with predominately *classic* subfoveal CNV lesions (where the area of classic CNV occupies  $\geq 50\%$  of the area of the entire lesion).

**Note:** Remember that this diagnosis must be determined by a fluorescein angiogram at the initial visit. Also, there are no requirements regarding visual acuity, lesion size, and number of re-treatments when treating predominantly classic lesion patients; however, they do require a fluorescein angiogram in subsequent, follow-up visits prior to treatment.

In addition to this diagnosis, after thorough review and reconsideration of the August 20, 2002 noncoverage policy, CMS has determined that there is enough evidence to conclude that OPT with verteporfin, in certain instances, may be reasonable and necessary for treating subfoveal occult lesions with no classic CNV and subfoveal minimally-classic CNV lesions (where the area of classic CNV occupies  $<50\%$  of the area of the entire lesion).

### *When Covered Indications are Reasonable and Necessary*

These two new covered indications are considered reasonable and necessary only when:

- The lesions are small (four disk areas or less in size) at the time of initial treatment or within the 3 months prior to initial treatment; and
- They have shown evidence of progression within the three months prior to initial treatment. You must confirm this evidence of progression by documenting:
  - The deterioration of visual acuity (at least five letters on a standard eye examination chart);
  - Lesion growth (an increase in at least one disk area); or

#### Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents.

- The appearance of blood associated with the lesion.

Be aware that the other AMD-related uses of OPT with verteporfin, not already addressed by CMS, will continue to be noncovered. These include, but are not limited to: juxtafoveal or extrafoveal CNV lesions (lesions outside the fovea); inability to obtain a fluorescein angiogram; or atrophic or “dry” AMD.

On the other hand, the use of OPT with verteporfin for other ocular indications, such as pathologic myopia or presumed ocular histoplasmosis syndrome, continue to be eligible for local coverage determinations through individual Medicare contractor discretion.

### *National Coverage Determination History*

The following is a short history leading up to the current NCD:

1. Effective July 1, 2001, CMS approved the use of OPT with verteporfin in neovascular AMD patients having predominately classic subfoveal CNV lesions.
2. On October 17, 2001, CMS announced its “intent to cover” OPT with verteporfin for AMD patients with occult subfoveal CNV lesions; however, this decision was never implemented.
3. On March 28, 2002, CMS reviewed the October 17, 2001 intent-to-cover policy, and determined that the (then) current noncoverage policy for OPT for verteporfin for AMD patients with occult subfoveal CNV should remain in effect.
4. Effective August 20, 2002, CMS issued a noncovered instruction for OPT with verteporfin for AMD patients with occult subfoveal CNV lesions.
5. Now CMS, after through review and reconsideration of the August 2002 decision, has determined that there is enough evidence to conclude that OPT with verteporfin is also reasonable and necessary in these additional clinical instances. Therefore, this NCD, effective April 1, 2004, provides for covering the use of OPT with verteporfin in patients with subfoveal occult lesions with no classic CNV, and subfoveal minimally classic CNV lesions as described above.

## **Additional Information**

---

Additional background information is available in Pub. 100-03, Chapters 80.2 and 80.3, which are included in the actual instruction issued to Medicare carriers and fiscal intermediaries on this NCD. This instruction can be found in CR3191 at <http://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R9NCD.pdf> on the CMS website.

### Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents.